Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448927 | 0.90 | CDK1 (0.44) | CA2SOS1GLO1CDK1CDK2 | |
| SCHEMBL3450272 | 0.87 | GRM4 (0.44) | GLO1CDK1CDK2KDR | |
| SCHEMBL3344933 | 0.81 | MAPK1 (0.47) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3344858 | 0.81 | MAPK1 (0.57) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3448567 | 0.80 | HDAC3 (0.46) | SOS1PTGS2CDK1CDK2KDR | |
| SCHEMBL13310349 | 0.79 | MAPK1 (0.54) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3345887 | 0.79 | APP (0.45) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3344899 | 0.78 | APP (0.54) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3350947 | 0.78 | MAPK1 (0.51) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3344452 | 0.78 | ABL1 (0.56) | CA12CA1CA2CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323324-A1 | MULTI-COMPONENT EPOXY RESIN MATERIAL WITH FINE FILLERS | Hilti Aktiengesellschaft (LI) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024017661-A1 | CHEMICAL ANCHOR SYSTEM | HILTI AKTIENGESELLSCHAFT (LI) | 2024-01-25 | — | — | WO | disclosed |
| EP-3526261-A1 | BETA-NUCLEATED PROPYLENE TERPOLYMER COMPOSITION WITH GOOD TOUGHNESS | Borealis AG (AT) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018069263-A1 | BETA-NUCLEATED PROPYLENE TERPOLYMER COMPOSITION WITH GOOD TOUGHNESS | BOREALIS AG (AT) | 2018-04-19 | — | — | WO | disclosed |
| CN-102746584-A | Pipes comprising beta-nucleated propylene copolymers | BOREALIS TECH OY | 2012-10-24 | — | — | CN | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010057841-A1 | PROPYLENE-BUTENE RANDOM COPOLYMER PRODUCED IN THE PRESENCE OF A METTALOCENE CATALYST | BOREALIS AG (AT) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057840-A1 | PROPYLENE-HEXENE RANDOM COPOLYMER PRODUCED IN THE PRESENCE OF A METALLOCENE CATALYST | BOREALIS AG (AT) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010037747-A1 | NEW SEWAGE PIPE MATERIAL WITH IMPROVED PROPERTIES | BOREALIS AG (AT) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CA12 1716/4885CA1 3580/4885CA2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.